YO-01027 (also called dibenzazepine; DBZ; YO01027) is a novel, potent, orally bioavailable, dipeptidic inhibitor of the γ-secretase with potential antineoplastic activity.

Semagacestat (also known as LY450139; LY4501) is a novel and potent γ-secretase inhibitor/blocker for Aβ42, Aβ40 and Aβ38 with the potential for treating Alzheimer’s disease.

LY411575 (also named as LY-411575; LY 411575; LSN-411575; LSN411575) is a dibenzoazepine-based, cell permeable and selective Gamma/γ-secretase inhibitor with potential anti-AD ( Alzheimer’s disease) activity.

FLI-06 (FLI 06; FLI-06) is a novel and potent inhibitor of Notch signaling pathway with EC50 of 2.3 μM.

DAPT (also known as GSI-IX; LY-374973) is a novel, potent and selective γ-secretase inhibitor used in the study of the Notch signaling pathway and is reported to be able to reduce the levels of beta-amyloid in a mouse model of Alzheimer’s disease.

Nirogacestat (formerly also known as PF-03084014; PF03084014; PF 3084014; PF-3084014) is an orally bioavailable, reversible, noncompetitive, and selective γ-secretase/gamma secretase (GS) inhibitor with potential anticancer activity.

Avagacestat (formerly known as BMS708163) is a potent, selective, orally bioactive γ -secretase inhibitor of Aβ40 and Aβ42 with potential anti-AD (Alzheimer’s disease) activity.

L-685,458 (also called L685458; L-685458) is a selective inhibitor of Aß PP γ-secretase with potential anti-AD and anticancer activity.

RO4929097 (also called RO-4929097; RO04929097; R-4733) is a novel, potent and orally bioavailable small molecule inhibitor of the γ-secretase (gamma secretase-GS) with potential antitumor activity.

MK0752 (MK0752; MK-0752) is a novel, potent and synthetic small molecule inhibitor of γ-secretase (gamma-secretase).